Sven Walderich, MD

Title(s)Resident, Medicine
SchoolSchool of Medicine
Address505 Parnassus Avenue
San Francisco CA 94117
Phone--
ORCID ORCID Icon0000-0003-3671-3494 Additional info
vCardDownload vCard

    Collapse Biography 
    Collapse Education and Training
    Weill Cornell Medicine , New YorkM.D.04/2020
    University of California, Santa Barbara, Santa BarbaraB.S.06/2015Biochemistry and Molecular Biology

    Collapse Overview 

    Collapse Bibliographic 
    Collapse Publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help. to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    Altmetrics Details PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. Targeting galectin-3 with a high-affinity antibody for inhibition of high-grade serous ovarian cancer and other MUC16/CA-125-expressing malignancies. Sci Rep. 2021 02 12; 11(1):3718. Stasenko M, Smith E, Yeku O, Park KJ, Laster I, Lee K, Walderich S, Spriggs E, Rueda B, Weigelt B, Zamarin D, Rao TD, Spriggs DR. PMID: 33580170; PMCID: PMC7881041.
      View in: PubMed   Mentions: 2     Fields:    Translation:AnimalsCells
    2. Safety, immunogenicity, and clinical efficacy of durvalumab in combination with folate receptor alpha vaccine TPIV200 in patients with advanced ovarian cancer: a phase II trial. J Immunother Cancer. 2020 06; 8(1). Zamarin D, Walderich S, Holland A, Zhou Q, Iasonos AE, Torrisi JM, Merghoub T, Chesebrough LF, Mcdonnell AS, Gallagher JM, Li Y, Hollmann TJ, Grisham RN, Erskine CL, Block MS, Knutson KL, O'Cearbhaill RE, Aghajanian C, Konner JA. PMID: 32503949; PMCID: PMC7279674.
      View in: PubMed   Mentions: 4     Fields:    Translation:HumansCTClinical Trials
    Sven's Networks
    Concepts (32)
    Derived automatically from this person's publications.
    Explore
    _
    Similar People (60)
    People who share similar concepts with this person.
    Explore
    _
    Same Department
    Search Department
    _

    UCSF Profiles is managed by the UCSF Clinical and Translational Science Institute (CTSI), part of the Clinical and Translational Science Award program funded by the National Center for Advancing Translational Sciences (Grant Number UL1 TR000004) at the National Institutes of Health (NIH).
    This site is running Profiles RNS version v3.1.0-871-g21b54b14 on PROFILES-PWEB02.

    Copyright © The Regents of the University of California